Aptivus Related Published Studies
Well-designed clinical trials related to Aptivus (Tipranavir)
Effects of tipranavir, darunavir, and ritonavir on platelet function, coagulation, and fibrinolysis in healthy volunteers. [2011.06.01]
Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers. [2011.03]
A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. [2010.06]
Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. [2010.01]
Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. [2008.11.12]
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir. [2008.10.01]
Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51). [2008.04.01]
Health-related quality of life and tolerability in treatment-experienced HIV-1-infected patients on tipranavir versus comparator regimens. [2008]
Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. [2007.08.01]
Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA. [2007.05]
Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. [2007.02]
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients. [2007.01.11]
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. [2006.11.15]
Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. [2006.11.15]
Interaction of ritonavir-boosted tipranavir with loperamide does not result in loperamide-associated neurologic side effects in healthy volunteers. [2005.12]
Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. [2004.11]
A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. [2004.04.01]
Well-designed clinical trials possibly related to Aptivus (Tipranavir)
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. [2011.09]
Pharmacokinetic interaction of vicriviroc with other antiretroviral agents: results from a series of fixed-sequence and parallel-group clinical trials. [2011.04.01]
Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV Type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. [2010.03.15]
Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience. [2010]
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients. [2010]
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. [2008.04]
Other research related to Aptivus (Tipranavir)
Boosted Tipranavir versus Darunavir in Treatment-Experienced Patients: Observational Data from the Randomized POTENT Trial. [2011.12.01]
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial. [2011.07]
Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. [2011.07]
Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. [2011.05]
Effects of tipranavir, darunavir, and ritonavir on platelet function,
coagulation, and fibrinolysis in healthy volunteers. [2011]
Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir
and single-dose valacyclovir in healthy volunteers. [2011]
Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice. [2010.11]
Efficacy and safety of ritonavir dose reduction based on the tipranavir inhibitory quotient in HIV-infected patients on salvage antiretroviral therapy with tipranavir/ritonavir. [2010.11]
Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. [2010.07]
Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: The UTILIZE Study. [2010.06]
The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. [2010.04]
[Adverse reactions of atazanavir, fosamprenavir and tipranavir in "real life"] [2010.03]
Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. [2010]
Pharmacokinetic characterization of three doses of tipranavir boosted with
ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1
patients. [2010]
A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug
interactions with the mixed inhibitor/inducer tipranavir/ritonavir. [2010]
Hepatic profile analyses of tipranavir in Phase II and III clinical trials. [2009.12.14]
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. [2009.12.01]
Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation. [2009.12]
Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). [2009.11]
A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. [2009.10.01]
Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. [2009.10]
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. [2009.10]
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. [2009.10]
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. [2009.09.14]
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir. [2009.07]
Reversal of major genotypic tipranavir mutations under long-term treatment with tipranavir/ritonavir itself with very limited optimized background, during deep salvage antiretroviral therapy. [2009.05]
Drug-excipient complexation in lipid based delivery systems: an investigation of the Tipranavir-1,3-dioctanolyglycerol complex. [2009.05]
Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. [2009.02.01]
Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. [2009.01.28]
A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide. [2009.01.28]
Hepatic safety of tipranavir plus ritonavir (TPV/r)-based antiretroviral combinations: effect of hepatitis virus co-infection and pre-existing fibrosis. [2009.01]
Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. [2009.01]
Comparison of the pharmacokinetics of apricitabine in the presence and absence of ritonavir-boosted tipranavir: a phase I, open-label, controlled, single-centre study. [2009]
Tipranavir: a new protease inhibitor for the pediatric population. [2008.12]
Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? [2008.11.01]
Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System. [2008.11]
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring. [2008.10.27]
Efficacy, safety and tolerability of tipranavir coadministered with ritonavir in HIV-1-infected children and adolescents. [2008.09.12]
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. [2008.09]
Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. [2008.07]
Intracranial haemorrhage possibly related to Tipranavir in an HIV-1 patient with cryptococcal meningitis. [2008.07]
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. [2008.03.12]
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. [2008.03]
Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. [2008.02]
Tipranavir exhibits different effects on opportunistic pathogenic fungi. [2008.01]
Tipranavir: a review of its use in the management of HIV infection. [2008]
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. [2007.11.22]
Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. [2007.11]
Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. [2007.10.18]
Tipranavir: a new option for the treatment of drug-resistant HIV infection. [2007.09.15]
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. [2007.09.12]
Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats. [2007.09]
Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice. [2007.09]
Steady-state disposition of the nonpeptidic protease inhibitor tipranavir when coadministered with ritonavir. [2007.07]
A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. [2007.04.01]
Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. [2007.04]
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. [2006.11]
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. [2006.08.05]
Determination of tipranavir in human plasma by reverse phase liquid chromatography with UV detection using photodiode array. [2006.08]
Tipranavir: a protease inhibitor for HIV salvage therapy. [2006.07]
A simple high performance liquid chromatography assay for monitoring plasma concentrations of tipranavir in HIV infected patients. [2006.03.07]
Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies. [2006.02]
Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. [2006.01]
Tipranavir: a novel nonpeptidic protease inhibitor of HIV. [2006]
Tipranavir. [2005.11]
Tipranavir: a novel second-generation nonpeptidic protease inhibitor. [2005.02]
Tipranavir: a ritonavir-boosted protease inhibitor. [2005]
Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. [2003.11]
Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. [2003.09]
Saquinavir: a review of its use in boosted regimens for treating HIV infection. [2003]
Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. [1999]
Other possibly related research studies
CCR5 Antagonists: Comparison of Efficacy, Side Effects, Pharmacokinetics and Interactions - Review of the Literature. [2007.10.15]
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. [2006]
An update and review of antiretroviral therapy. [2006.08]
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. [2006.03]
Management of HIV-infected patients with multidrug-resistant virus. [2004.09]
Strategies for overcoming resistance in HIV-1 infected patients receiving HAART. [2004.07]
The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients. [2004.06]
|
